Skip to main content
. 2012 Feb 22;32(8):2683–2695. doi: 10.1523/JNEUROSCI.4125-11.2011

Figure 8.

Figure 8.

Nrb−/− mice exhibit enhanced A1R-mediated anticonvulsant effects against kainate-induced seizures. A, Seizure severity in response to kainate (KA) is attenuated in Nrb−/− mice. Seizure activity over time following kainate injection (25 mg/kg, i.p.; n = 13 for WT and n = 11 for Nrb−/−) or kainate coinjection with the A1R antagonist DPCPX (0.5 mg/kg) (n = 9 for WT, n = 8 for Nrb−/−) was scored as described in Materials and Methods with a higher score indicating greater seizure severity. *p < 0.05; **p < 0.01; ***p < 0.001, Nrb−/− versus WT mice. #p < 0.05; ##p < 0.01, WT mice treated with kainate alone versus kainate plus DPCPX. B, Kainate-induced lethality is reduced in Nrb−/− mice. Data are expressed as a percentage of death in WT (n = 13) and Nrb−/− (n = 11) mice caused by administration of kainate (25 mg/kg) alone or with DPCPX. C, The percentage of mice with generalized seizure is reduced in Nrb−/− mice. The percentage of mice with generalized seizure within 120 min post-kainate administration at 20 mg/kg (WT n = 8; Nrb−/− n = 8) or 25 mg/kg (WT n = 13; Nrb−/− n = 11) was calculated for each genotype.